Mapping of CBV changes in 5-HT1A terminal fields by functional MRI in the mouse brain

European Neuropsychopharmacology

Volumn 21, Issue 4, 2011, Pages 344-353

  Mueggler, Thomas ^a,d   Razoux, Florence ^a   Russig, Holger ^b   Buehler, Anna ^a   Franklin, Tamara B ^b   Baltes, Christof ^a   Mansuy, Isabelle M ^b   Rudin, Markus ^a,c  

^a ETH ZURICH   (Switzerland)

^b University of Zurich Brain Research Institute   (Switzerland)

^c UNIVERSITY OF ZURICH   (Switzerland)

^d F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

5 HT1A receptor; 5 HT1A receptor knockout mice; 8 OH DPAT; Functional MRI; WAY 100635

Indexed keywords

2 DIPROPYLAMINO 8 HYDROXYTETRALIN; N [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] N (2 PYRIDYL)CYCLOHEXANECARBOXAMIDE; SEROTONIN 1A RECEPTOR;

AMYGDALOID NUCLEUS; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRAIN BLOOD VOLUME; BRAIN MAPPING; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; FUNCTIONAL MAGNETIC RESONANCE IMAGING; HIPPOCAMPUS; MALE; MOUSE; NONHUMAN; PREFRONTAL CORTEX; PRIORITY JOURNAL; SEROTONINERGIC SYSTEM; SEROTONINERGIC TRANSMISSION;

8-HYDROXY-2-(DI-N-PROPYLAMINO)TETRALIN; ANATOMY, CROSS-SECTIONAL; ANIMALS; BRAIN; BRAIN MAPPING; DOSE-RESPONSE RELATIONSHIP, DRUG; FEASIBILITY STUDIES; KINETICS; MAGNETIC RESONANCE IMAGING; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; NERVE TISSUE PROTEINS; NEURONS; PIPERAZINES; PYRIDINES; RECEPTOR, SEROTONIN, 5-HT1A; REGIONAL BLOOD FLOW; SEROTONIN 5-HT1 RECEPTOR AGONISTS; SEROTONIN 5-HT1 RECEPTOR ANTAGONISTS;

EID: 79952359509     PISSN: 0924977X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.euroneuro.2010.06.010     Document Type: Article

References (67)

1. Albert P.R., Lemonde S. 5-HT1A receptors, gene repression, and depression: guilt by association. Neuroscientist 2004, 10:575-593.
2. Anderson I.M., McKie S., Elliott R., Williams S.R., Deakin J.F. Assessing human 5-HT function in vivo with pharmacoMRI. Neuropharmacology 2008, 55:1029-1037.
3. Arvidsson L.E., Hacksell U., Nilsson J.L., Hjorth S., Carlsson A., Lindberg P., Sanchez D., Wikstrom H. 8-Hydroxy-2-(di-n-prpylamino)tetralin, a new centrally acting 5-hydroxytryptamine receptor agonist. J. Med. Chem. 1981, 24:921-923.
4. Assié M.B., Koek W. Effects of 5-HT1A receptor antagonists on hippocampal 5-hydroxytryptamine levels: (S)-WAY100135, but not WAY-100635, has partial agonist properties. Eur. J. Pharmacol. 1996, 304:15-21.
5. Baltes C., Radzwill N., Bosshard S., Marek D., Rudin M. Micro MR imaging of the mouse brain using a novel 400MHz cryogenic quadrature RF probe. NMR Biomed. 2009, 22:834-842.
6. Bard J.A., Zgombick J., Adham N., Vaysse P., Branchek T.A., Weinshank R.L. Cloning of a novel human serotonin receptor (5-HT7) positively linked to adenylate cyclase. J. Biol. Chem. 1993, 268:23422-23426.
7. Barnes N.M., Sharp T. A review of central 5-HT receptors and their function. Neuropharmacology 1999, 38:1083-1152.
8. Blier P., Ward N.M. Is there a role for 5-HT1A agonists in the treatment of depression?. Biol. Psychiatry 2003, 53:193-203.
9. Blier P., Piñeyro G., el Mansari M., Bergeron R., de Montigny C. Role of somatodendritic 5-HT autoreceptors in modulating 5-HT neurotransmission. Ann. NY Acad. Sci. 1998, 861:204-216.
10. Bockaert J., Claeysen S., Bécamel C., Dumuis A., Marin P. Neuronal 5-HT metabotropic receptors: fine-tuning of their structure, signaling, and roles in synaptic modulation. Cell Tissue Res. 2006, 326:553-572.
11. Borsook D., Becerra L., Hargreaves R. A role for fMRI in optimizing CNS drug development. Nat. Rev. Drug Discov. 2006, 5:411-424.
12. Celada P., Puig M.V., Martín-Ruiz R., Casanovas J.M., Artigas F. Control of the serotonergic system by the medial prefrontal cortex: potential role in the etiology of PTSD and depressive disorders. Neurotox. Res. 2002, 4:409-419.
13. Centurion D., Mehotra S., Sánchez-López A., Gupta S., Maassen VanDenBrink A., Villalón C.M. Potential vascular α1-adrenoceptor blocking properties of an array of 5-HT receptor ligands in the rat. Eur. J. Pharmacol. 2006, 535:234-242.
14. Chen Y.C., Galpern W.R., Brownell A.L., Matthews R.T., Bogdanov M., Isacson O., Keltner J.R., Beal M.F., Rosen B.R., Jenkins B.G. Detection of dopaminergic neurotransmitter activity using pharmacologic MRI: correlation with PET, microdialysis, and behavioral data. Magn. Reson. Med. 1997, 38:389-398.
15. Chessell I.P., Francis P.T., Pangalos M.N., Pearson R.C., Bowen D.M. Localisation of muscarinic (m1) and other neurotransmitter receptors on corticofugalprojecting pyramidal neurones. Brain Res. 1993, 632:86-94.
16. Czyrak A., Czepiel K., Mackowiak M., Chocyk A., Wedzony K. Serotonin 5-HT1A receptors might control the output of cortical glutamatergic neurons in rat cingulate cortex. Brain Res. 2003, 989:42-51.
17. Descarries L., Watkins K.C., Garcia S., Beaudet A. The serotonin neurons in nucleus raphe dorsalis of adult rat: a light and electron microscope radioautographic study. J. Comp. Neurol. 1982, 207:239-254.
18. Drevets W.C., Frank E., Price J.C., Kupfer D.J., Holt D., Greer P.J., Huang Y., Gautier C., Mathis C. PET imaging of serotonin 1A receptor binding in depression. Biol. Psychiatry 1999, 46:1375-1387.
19. Fletcher A., Bill D.J., Bill S.J., Cliffe I.A., Dover G.M., Forster E.A., Haskins J.T., Jones D., Mansell H.L., Reilly Y. WAY100135: a novel, selective antagonist at presynaptic and postsynaptic 5-HT1A receptors. Eur. J. Pharmacol. 1993, 237:283-291.
20. Fletcher A., Forster E.A., Bill D.J., Brown G., Cliffe I.A., Hartley J.E., Jones D.E., Mclenachan A., Stanhope K.J., Critchley D.J.P., Childs K.J., Middlefell V.C., Lanfumey L., Corradetti R., Laporte A.M., Gozlan H., Hamon M., Dourish C.T. Electrophysiological, biochemical, neurohormonal and behavioural studies with WAY-100635, a potent, selective and silent 5-HT1A receptor antagonist. Behav. Brain Res. 1996, 73:337-353.
21. Freo U. Cerebral metabolic effects of serotonin drugs and neurotoxins. Life Sci. 1996, 59:877-891.
22. Garner M., Möhler H., Stein D.J., Mueggler T., Baldwin D.S. Research in anxiety disorders: from the bench to the bedside. Eur. Neuropsychopharmacol. 2009, 19:381-390.
23. Gingrich J.A., Hen R. Dissecting the role of the serotonin system in neuropsychiatric disorders using knockout mice. Psychopharmacology 2001, 155:1-10.
24. Graeff F.G. On serotonin and experimental anxiety. Psychopharmacology 2002, 163:467-476.
25. Gross C., Zhuang X.X., Stark K., Ramboz S., Oosting R., Kirby L., Santarelli L., Beck S., Hen R. Serotonin(1A)receptor acts during development to establish normal anxiety-like behaviour in the adult. Nature 2002, 416:396-400.
26. Gustafson E.L., Durkin M.M., Bard J.A., Zgombick J., Branchek T.A. A receptor autoradiographic and in situ hybridization analysis of the distribution of the 5-HT7 receptor in rat brain. Br. J. Pharmacol. 1996, 117:657-666.
27. Hackler E.A., Turner G.H., Gresch P.J., Sengupta S., Deutch A.Y., Avison M.J., Gore J.C., Sanders-Bush E. 5-Hydroxytryp.tamine2C receptor contribution to m-chlorophenylpiperazine and N-methyl-beta-carboline-3-carboxamide-induced anxiety-like behavior and limbic brain activation. J. Pharmacol. Exp. Ther. 2007, 320:1023-1029.
28. Hannon J., Hoyer D. Molecular biology of 5-HT receptors. Behav. Brain Res. 2008, 195:198-213.
29. Hedlund P.B., Kelly L., Mazurb C., Lovenberg T., Sutcliffe J.G., Bonaventure P. 8-OH-DPAT acts on both 5-HT1A and 5-HT7 receptors to induce hypothermia in rodents. Eur. J. Pharmacol. 2004, 487:125-132.
30. Hennig J., Nauerth A., Friedburg H. RARE imaging: a fast imaging method for clinical MR. Magn. Reson. Med. 1986, 3:823-833.
31. Hillegaart V., Hjorth S., Ahlenius S. Effects of 5-HT and 8-OH-DPAT on forebrain monoamine synthesis after local application into the median and dorsal raphe nuclei of the rat. J. Neural Transm. Gen. Sect. 1990, 81:131-145.
32. Hirvonen J., Karlsson H., Kajander J., Lepola A., Markkula J., Rasi-Hakala H., Någren K., Salminen J.K., Hietala J. Decreased brain serotonin 5-HT1A receptor availability in medication-naive patients with major depressive disorder: an in-vivo imaging study using PET and (carbonyl-11C)WAY-100635. Int. J. Neuropsychopharmacol. 2008, 11:465-476.
33. Hjorth S., Sharp T. Effect of the 5-HT1A receptor agonist 8-OH-DPAT on the release of 5-HT in dorsal and median raphe-innervated rat brain regions as measured by in vivo microdialysis. Life Sci. 1991, 48:1779-1786.
34. Houston G.C., Papadakis N.G., Carpenter T.A., Hall L.D., Mukherjee B., James M.F., Huang C.L.-H. Mapping of brain activation in response to pharmacological agents using fMRI in the rat. Magn. Reson. Imaging 2001, 19:905-919.
35. Hoyer D., Pazos A., Probst A., Palacios J.M. Serotonin receptors in the human brain. I. Characterization and autoradiographic localization of 5-HT1A recognition sites. Apparent absence of 5-HT1B recognition sites. Brain Res. 1986, 376:85-96.
36. Jagoda E.M., Lang L., Tokugawa J., Simmons A., Ma Y., Contoreggi C., Kiesewetter D., Eckelman W.C. Development of 5-HT1A receptor radioligands to determine receptor density and changes in endogenous 5-HT. Synapse 2006, 59:330-341.
37. Jones N., O'Neill M.J., Tricklebank M., Libri V., Williams S.C. Examining the neural targets of the AMPA receptor potentiator LY404187 in the rat brain using pharmacological magnetic resonance imaging. Psychopharmacology 2005, 180:743-751.
38. Kumar J.S., Mann J.J. PET tracers for 5-HT(1A) receptors and uses thereof. Drug Discov. Today 2007, 12:748-756.
39. Kuriwaki J., Nishijo H., Kondoh T., Uwano T., Torii K., Katsuki M., Ono T. Comparison of brain activity between dopamine D2 receptor-knockout and wild mice in response to dopamine agonist and antagonist assessed by fMRI. Neurosignals 2004, 13:227.
40. Lanfumey L., Hamon M. Central 5-HT(1A) receptors: regional distribution and functional characteristics. Nucl. Med. Biol. 2000, 27:429-435.
41. Lanzenberger R.R., Mitterhauser M., Spindelegger C., Wadsak W., Klein N., Mien L.K., Holik A., Attarbaschi T., Mossaheb N., Sacher J., Geiss-Granadia T., Kletter K., Kasper S., Tauscher J. Reduced serotonin-1A receptor binding in social anxiety disorder. Biol. Psychiatry 2007, 61:1081-1089.
42. Laporte A.M., Lima L., Gozlan H., Hamon M. Selective in vivo labelling of brain 5-HT1A receptors by (3H)WAY 100635 in the mouse. Eur. J. Pharmacol. 1994, 271:505-514.
43. Martin C., Sibson N.R. Pharmacological MRI in animal models: a useful tool for 5-HT research?. Neuropharmacology 2008, 55:1038-1047.
44. Martín-Ruiz R., Ugedo L. Electrophysiological evidence for postsynaptic 5-HT(1A) receptor control of dorsal raphe 5-HT neurones. Neuropharmacology 2001, 41:72-78.
45. Mueggler T. Magnetic resonance imaging and spectroscopy in transgenic mice modeling Alzheimer's disease. In-vivo MRI/MRS in Biological Systems 2006, 95-110. Taylor & Francis Group, New York. N. Beckmann (Ed.).
46. Mueggler T., Baumann D., Rausch M., Rudin M. Bicuculline-induced brain activation in mice detected by functional magnetic resonance imaging. Magn. Reson. Med. 2001, 46:292-298.
47. Mueggler T., Sturchler-Pierrat C., Baumann D., Rausch M., Staufenbiel M., Rudin M. Compromised hemodynamic response in amyloid precursor protein transgenic mice. J. Neurosci. 2002, 22:7218-7224.
48. Mueggler T., Baumann D., Rausch M., Staufenbiel M., Rudin M. Age-dependent impairment of somatosensory response in the amyloid precursor protein 23 transgenic mouse model of Alzheimer's disease. J. Neurosci. 2003, 23:8231-8236.
49. Neumeister A., Young T., Stastny J. Implications of genetic research on the role of the serotonin in depression: emphasis on the serotonin type 1A receptor and the serotonin transporter. Psychopharmacology 2004, 174:512-524.
50. Olivier B., Pattij T., Wood S.J., Oosting R., Sarnyai Z., Toth M. The 5-HT(1A) receptor knockout mouse and anxiety. Behav. Pharmacol. 2001, 12:439-450.
51. Parks C.L., Robinson P.S., Sibille E., Shenk T., Toth M. Increased anxiety of mice lacking the serotonin(1A) receptor. Proc. Natl. Acad. Sci. U. S. A. 1998, 95:10734-10739.
52. Pattij T., Groenink L., Oosting R.S., van der Gugten J., Maes R.A., Olivier B. GABA(A)-benzodiazepine receptor complex sensitivity in 5-HT(1A) receptor knockout mice on a 129/Sv background. Eur. J. Pharmacol. 2002, 447:67-74.
53. Paxinos G., Franklin K.B.J. The Mouse Brain in Stereotaxic Coordinates 2001, Academic Press, San Diego.
54. Ramboz S., Oosting R., Amara D.A., Kung H.F., Blier P., Mendelsohn M., Mann J.J., Brunner D., Hen R. Serotonin receptor 1A knockout: an animal model of anxiety-related disorder. Proc. Natl. Acad. Sci. U. S. A. 1998, 95:14476-14481.
55. Ratering D., Baltes C., Nordmeyer-Massner J., Marek D., Rudin M. Performance of a 200-MHz cryogenic RF probe designed for MRI and MRS of the murine brain. Magn. Reson. Med. 2008, 59:1440-1447.
56. Reese T., Bjelke B., Porszasz R., Baumann D., Bochelen D., Sauter A., Rudin M. Regional brain activation by bicuculline visualized by functional magnetic resonance imaging. Time-resolved assessment of bicuculline-induced changes in local cerebral blood volume using an intravascular contrast agent. NMR Biomed. 2000, 13:43-49.
57. Rudin M., Mueggler T., Allegrini P.R., Baumann D., Rausch M. Characterization of CNS disorders and evaluation of therapy using structural and functional MRI. Anal. Bioanal. Chem. 2003, 377:973-981.
58. Savitz J., Lucki I., Drevets W.C. 5-HT(1A) receptor function in major depressive disorder. Prog. Neurobiol. 2009, 88:17-31.
59. Scanley B.E., Kennan R.P., Gore J.C. Changes in rat cerebral blood volume due to modulation of the 5-HT(1A) receptor measured with susceptibility enhanced contrast MRI. Brain Res. 2001, 913:149-155.
60. Sprouse J.S., Aghajanian G.K. Responses of hippocampal pyramidal cells to putative serotonin 5-HT1A and 5-HT1B agonists: a comparative study with dorsal raphe neurons. Neuropharmacology 1988, 27:707-715.
61. Stark J.A., Davies K.E., Williams S.R., Luckman S.M. Functional magnetic resonance imaging and c-Fos mapping in rats following an anorectic dose of m-chlorophenylpiperazine. Neuroimage 2006, 31:1228-1237.
62. Stark J.A., McKie S., Davies K.E., Williams S.R., Luckman S.M. 5-HT2C antagonism blocks blood oxygen level-dependent pharmacological-challenge magnetic resonance imaging signal in rat brain areas related to feeding. Eur. J. Neurosci. 2008, 27:457-465.
63. Sullivan G.M., Oquendo M.A., Simpson N., Van Heertum R.L., Mann J.J., Parsey R.V. Brain serotonin 1A receptor binding in major depression is related to psychic and somatic anxiety. Biol. Psychiatry 2005, 58:947-954.
64. Toth M. 5-HT1A receptor knockout mouse as a genetic model of anxiety. Eur. J. Pharmacol. 2003, 463:177-184.
65. Van der Linden A., Van Camp N., Ramos-Cabrer P., Hoehn M. Current status of functional MRI on small animals: application to physiology, pathophysiology, and cognition. NMR Biomed. 2007, 20:522-545.
66. Wood M.D. Therapeutic potential of 5-HT2C receptor antagonists in the treatment of anxiety disorders. Curr. Drug Targets CNS Neurol. Disord. 2003, 2:383-387.
67. Yoshio R., Taniguchi T., Itoh H., Muramatsu I. Affinity of serotonin receptor antagonists and agonists to recombinant and native alpha1-adrenoceptor subtypes. Jpn J. Pharmacol. 2001, 86:189-195.